Helomics Starts AI-based Tumor Sequencing Aimed at Predicting OC Treatment Responses

Helomics Starts AI-based Tumor Sequencing Aimed at Predicting OC Treatment Responses
Helomics, a subsidiary of Predictive Oncology, has begun sequencing tumor samples as part of its collaboration with UPMC Magee Women’s Hospital. The partners aim to use artificial intelligence (AI) to help better predict treatment responses for people with ovarian cancer. The collaboration will use Helomics's AI platform, which is called D-CHIP, to analyze genomic and treatment response profiles. Based on multi-faceted analysis of tumor data — for example, information on mutations, tumor gene expression, and tumor tissue configuration — the researchers are ultimately hoping to identify individuals who are more likely to respond to a given therapy. That would allow the most effective treatment to be given to each patient. "These retrospective ovarian cancer cases were profiled Helomics as early as 2010; hence, we have 10 years’ worth of drug treatment data, survival and other outcome measures we are gathering from Magee’s clinical databases," Mark A. Collins, PhD, the chief innovation officer at Helomics, said in a
Subscribe or to access all post and page content.